Abbreviations: + : present; -: absent; M: male, F: female; *: included in reference, 2 C: consanguinity, N: no family history, 1S or 2S: number of other affected sibs, Clinical Presentation, Mu: muscle, C: central nervous system, H: heart, L: liver, mt prolif: mitochondrial proliferation, N: no data, CC: corpus callosum; LA: lactic acidosis, PEO: progressive external ophthalmoparesis, OA: optic atrophy, AN: axonal neuropathy, FTT: failure to thrive, leukoenceph: leukoencephalopathy, CSF: cerebrospinal fluid, CK: creatine kinase, RRF: ragged red fibers, COX: cytochrome c oxidase; SDH: succinate dehydrogenase, underlined genes (C): known disease genes, but clinical presentation is not compatible with this gene defect, H and L : respiratory chain measurement was performed in H heart and L liver. Hom: homozygous. ↓↓: severe biochemical defect, ↓: mild biochemical defect, segregation analysis, where A: number of affecteds screened (including the index patient), U: number of unaffecteds (including sibs and parents). A = number of affected individuals genotyped within the family, U = number of unaffected individuals genotyped in the family. Where indicated, all of the variants segregated appropriately with the phenotype. Biochemical data has been reported previously for some cases (* in Table 1 ) before a genetic diagnosis was possible.
2-4 (A) Presumptive pathogenic variants = homozygous or compound heterozygous mutations in genes previously shown to cause multiple respiratory chain complex deficiencies. Abbreviations: + : present; -: absent; M: male, F: female; *: included in reference, 2 C: consanguinity, N: no family history, 1S or 2S: number of other affected sibs, Clinical Presentation, Mu: muscle, C: central nervous system, H: heart, L: liver, mt prolif: mitochondrial proliferation, N: no data, CC: corpus callosum; LA: lactic acidosis, PEO: progressive external ophthalmoparesis, OA: optic atrophy, AN: axonal neuropathy, FTT: failure to thrive, leukoenceph: leukoencephalopathy, CSF: cerebrospinal fluid, CK: creatine kinase, RRF: ragged red fibers, COX: cytochrome c oxidase; SDH: succinate dehydrogenase, underlined genes (C): known disease genes, but clinical presentation is not compatible with this gene defect, H and L : respiratory chain measurement was performed in H heart and L liver. Hom: homozygous. ↓↓: severe biochemical defect, ↓: mild biochemical defect, segregation analysis, where A: number of affecteds screened (including the index patient), U: number of unaffecteds (including sibs and parents). A = number of affected individuals genotyped within the family, U = number of unaffected individuals genotyped in the family. Where indicated, all of the variants segregated appropriately with the phenotype. Biochemical data has been reported previously for some cases (* in Table 1 ) before a genetic diagnosis was possible.
B) Variants of interest
2-4 (B) Possible pathogenic variants = homozygous or compound heterozygous mutations in novel genes which may cause a mitochondrial translation defect based on their predicted function and similarity to known disease genes. Table 1 ) before a genetic diagnosis was possible.
C) Variants of unknown significance
2-4 (C) Variants of unknown significance = homozygous or compound heterozygous mutations in novel or known disease genes not known to be associated with mitochondrial pathology. Table 1 ) before a genetic diagnosis was possible.
D) Unresolved
2-4 (D) Unresolved = patients where a single plausible genetic cause could not be identified. Biochemical defects were classified as mild if the respiratory chain complex activities were below the reference range for the Newcastle-upon-Tyne or Munich laboratories, but greater than 30% of the lower limit of normal. Biochemical defects were classified as severe if the respiratory chain complex activities were less than 30% of the lower limit of normal. Coverage calculated for Consensus Coding Sequence (CCDS) bases (31,935,069 bp). Variants 'on-target' to Illumina Truseq 62Mb targets +/-500bp. SNV = single nucleotide variant.
